MCF10A-HER2 Cell Line
Invented by Ateequllah Hayat , Gabriella Ficz
Invented at Queen Mary University of London
- Datasheet
- References (0)
- Inventor Info
Info
| Catalogue Number | 157986 |
| Antigen/Gene or Protein Targets | Human Epidermal Receptor 2 (HER2/EBB2/neu), overexpressed in 25% breast cancers, treatments include Trastuzumab and Lapatinib. This plasmid also contains GFP for selection and tracking purposes. |
| Parental Line | MCF10A |
| Tissue | Breast |
| Disease Keywords | Breast cancer |
| Model | Immortalised Line |
| Relevance | Expressed at low levels in normal breast tissues but overexpressed in a subset of breast and ovarian cancers. |
| Production Details | Inducible HER2 construct was stably transduced in MCF10A cell line using a third generation lentiviral transduction system. |
| Conditional | Yes |
| Conditional Description | Conditional HER2 expression under tetracyline response element (TRE) regulated by the addition of doxycyline in breast epithelial cell line (MCF10A). |
| Research Area | Cancer |
| Positive Control | Any other HER2 cell line such as BT474 may be used as a positive control. |
| Notes | The GFP is in the same construct as the inducible HER2 but both genes are regulated by two different promoters. GFP expression is under the control of a weak EF1α promoter whereas the HER2 is induced by a strong TRE promoter. |
References
There are 0 reference entries for this reagent.
References: 0 entry
There is no reference for this reagent yet, feel free to use the button below to suggest one.
Add a reference
References: 0 entry
There is no reference for this reagent yet, feel free to use the button below to suggest one.
Add a reference
Inventor Information
Inventors
|
Ateequllah Hayat |
|
|
Gabriella Ficz |
